SCHEMBL22644635

SCHEMBL22644635

BCC(=O)N(CCNC)CC(=O)NC

nearest known ligand 0.31

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PRMT3 O60678 1/20 0.31
CARM1 Q86X55 1/20 0.31
PRMT6 Q96LA8 1/20 0.31
PRMT1 Q99873 1/20 0.31
PRMT8 Q9NR22 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL887936 0.94
SCHEMBL2742878 0.85 CA12 (0.38)
SCHEMBL1644155 0.84 PRMT3 (0.32) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL10047099 0.84 KDM4A (0.37) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL14073678 0.84 PRMT3 (0.32) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL16158824 0.82
SCHEMBL9887118 0.82 HDAC3 (0.32)
SCHEMBL17449863 0.82
SCHEMBL23951850 0.82 PRMT3 (0.31) PRMT3CARM1PRMT6PRMT1PRMT8
SCHEMBL14073677 0.82 PRMT3 (0.31) PRMT3CARM1PRMT6PRMT1PRMT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158166-A1 BIOLOGICALLY ACTIVE COMPOUNDS SUTURA THERAPEUTICS LTD (GB) 2023-05-25 US disclosed
US-20230158166-A1 BIOLOGICALLY ACTIVE COMPOUNDS SUTURA THERAPEUTICS LTD (GB) 2023-05-25 US disclosed
US-11541124-B2 Biologically active compound conjugated to a stapled or stitched peptide SUTURA THERAPEUTICS LTD (TC) 2023-01-03 US disclosed
US-20200353092-A1 BIOLOGICALLY ACTIVE COMPOUND CONJUGATED TO A STAPLED OR STITCHED PEPTIDE SUTURA THERAPEUTICS LTD (TC) 2020-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11541124-B2 Biologically active compound conjugated to a stapled or stitched peptide BPGM, TMPO, SLC7A1 PRMT3 2832/4885CARM1 1143/4885PRMT6 2156/4885
US-20200353092-A1 BIOLOGICALLY ACTIVE COMPOUND CONJUGATED TO A STAPLED OR STITCHED PEPTIDE BPGM, TMPO, SLC7A1 PRMT3 2865/4885CARM1 1166/4885PRMT6 2179/4885
US-20230158166-A1 BIOLOGICALLY ACTIVE COMPOUNDS BPGM, PICALM, TMPO PRMT3 3022/4885CARM1 1085/4885PRMT6 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.